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Commentary
Intravascular thrombosis plays a fundamental role in the 
pathophysiology of cardiac arrest. Autopsy results from 
cases of unsuccessful resuscitation and coronary angio-
graphy in survivors of out-of-hospital cardiac arrest 
suggest that 50-70% of deaths can be attributed to 
thrombosis in the form of myocardial infarction or 
pulmonary embolism [2,3]. Ischemia and reperfusion 
during resuscitation from cardiac arrest cause endothelial 
cell dysfunction, platelet activation, disseminated intra-
vascular coagulation, relatively low ﬁ   brinolysis, and a 
propensity for microcirculatory clot formation [4,5]. 
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Background
Approximately 70% of persons who have an out-of-hospital cardiac arrest have underlying acute myocardial infarction 
or pulmonary embolism. Therefore, thrombolysis during cardiopulmonary resuscitation may improve survival.
Methods
Objective: To determine whether thrombolysis with the use of tenecteplase during cardiopulmonary resuscitation 
can improve survival in adults with witnessed out-of-hospital arrest of presumed cardiac origin.
Design: Prospective, randomized, double-blind, placebo-controlled, multicenter trial.
Setting: 66 European emergency medical-service systems.
Subjects: 1050 adult patients with witnessed out-of-hospital cardiac arrest.
Intervention: We randomly assigned adult patients with witnessed out-of-hospital cardiac arrest to receive 
tenecteplase or placebo during cardiopulmonary resuscitation. Adjunctive heparin or aspirin was not used.
Outcomes: The primary end point was 30-day survival; the secondary end points were hospital admission, return of 
spontaneous circulation, 24-hour survival, survival to hospital discharge, and neurologic outcome.
Results
After blinded review of data from the fi  rst 443 patients, the data and safety monitoring board recommended 
discontinuation of enrollment of asystolic patients because of low survival, and the protocol was amended. 
Subsequently, the trial was terminated prematurely for futility after enrolling a total of 1050 patients. Tenecteplase 
was administered to 525 patients and placebo to 525 patients; the two treatment groups had similar clinical profi  les. 
We did not detect any signifi  cant diff  erences between tenecteplase and placebo in the primary end point of 30-day 
survival (14.7% vs. 17.0%; P=0.36; relative risk, 0.87; 95% confi  dence interval, 0.65 to 1.15) or in the secondary end 
points of hospital admission (53.5% vs. 55.0%, P=0.67), return of spontaneous circulation (55.0% vs. 54.6%, P=0.96), 
24-hour survival (30.6% vs. 33.3%, P=0.39), survival to hospital discharge (15.1% vs. 17.5%, P=0.33), or neurologic 
outcome (P=0.69). There were more intracranial hemorrhages in the tenecteplase group.
Conclusions
When tenecteplase was used without adjunctive antithrombotic therapy during advanced life support for out-of-
hospital cardiac arrest, we did not detect an improvement in outcome, in comparison with placebo. (ClinicalTrials.gov 
number, NCT00157261.)
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© 2010 BioMed Central LtdMicro  circulatory thrombosis leading to a “no-reﬂ  ow” 
phenomenon after return of spontaneous circulation may 
contribute to poor neurological function after cardiac arrest 
[6,7]. A number of studies have evaluated the eﬃ   cacy of 
thrombolysis during out-of-hospital cardiopul  mo  nary 
resuscitation. A meta-analysis of these studies, including 
one prospective and seven retrospective studies, demon-
strated an improvement in return of spontaneous 
circulation, survival to admission, 24-hour survival, hospital 
discharge, and neurological outcome [8]. Based on these 
results, the authors concluded that a large, randomized, 
multicenter study should be conducted to determine the 
eﬃ   cacy of thrombolysis during cardiac arrest.
Th  e Th  rombolysis in Cardiac Arrest (TROICA) trial 
investigators conducted a prospective double-blind, 
randomized, placebo-controlled trial in 66 European 
emergency medical-service systems (EMS) [1]. Adults 
with witnessed out-of-hospital cardiac arrest with an 
EMS response time of less than ten minutes were eligible 
for the study. Th  e study protocol permitted open-label 
use of thrombolytics rather than randomization for cases 
in which pulmonary embolism was suspected as the 
cause of arrest. Patients with an initial rhythm of asystole 
or pulseless electrical activity were immediately random-
ized to weight-based tenecteplase or placebo, and 
patients with ventricular ﬁ  brillation or pulseless ventri-
cular tachycardia were randomized after three failed 
attempts at deﬁ  brillation. Adjunctive antithrombotic and 
antiplatelet agents were not administered. Th  e trial was 
suspended after futility analyses were performed on data 
from 653 patients. A total of 1050 patients were enrolled 
and no patient was lost to 30-day follow-up. Th  e  baseline 
characteristics of the two groups were well matched in 
terms of age, comorbidities, and long-term medications, 
including aspirin and warfarin. EMS response times were 
similar between groups and median time to study drug 
administration was 18 minutes. Th  e circumstances of 
cardiac arrest were similar between groups, including the 
initial rhythm, cardiopulmonary resuscitation (CPR) by 
bystanders, and deﬁ   brillation administered by ﬁ  rst 
responder. Th   ere was no diﬀ  erence between tenecteplase 
and placebo in the primary endpoint of 30-day survival 
or for any of the secondary endpoints, though there was a 
higher rate of intracranial hemorrhage in the tenecteplase 
group. Th   e authors concluded that tenecteplase without 
an adjunctive antithrombotic during CPR does not 
improve outcome for out-of-hospital cardiac arrest.
Th   e TROICA trial has several strengths, including the 
large sample size, multicenter design, evaluation of 
clinically important outcomes, and complete follow-up 
for the primary endpoint. Of particular note is the time 
to thrombolysis of 18 minutes from collapse, which 
represents a signiﬁ  cantly shorter time than the typical 30 
minutes cited in previous studies. Despite these 
strengths, the study is subject to a few important 
limitations. Most detailled information regarding in-
hospital care was lacking, which may have aﬀ  ected the 
primary outcome of 30-day survival. In addition, survival 
data may be subject to selection bias as the authors 
allowed – for ethical reasons – the open-label use of 
thrombolytics for suspected pulmonary embolism, 
potentially excluding from randomization a subgroup of 
patients likely to beneﬁ   t from thrombolysis. Despite 
these limitations, the TROICA Trial convincingly 
demon  strates no mortality beneﬁ   t from thrombolysis 
with tenecteplase and an increase risk of asymptomatic 
intracranial hemorrhage in patients with out-of-hospital 
cardiac arrest.
Th   e search for new interventions to improve outcomes 
for out-of-hospital cardiac arrest remains elusive. Why 
did the current trial fail to show a beneﬁ  t for thrombolysis 
despite a strong biologic rationale and a suggestion of 
beneﬁ   t in prior, albeit smaller, studies? Decreased 
perfusion pressure may have prevented drug delivery and 
reduced the eﬃ   cacy of thrombolytics. Alternatively, the 
negative result seen in the TROICA trial could be 
ascribed to a lack of adjunctive antithrombotic or 
antiplatelet agents, given that all eight studies in the Li et 
al meta-analysis used heparin with or without aspirin [8]. 
Th   e most likely explanation, however, may be the law of 
diminishing returns. Th  e TROICA trial was conducted 
within a well-optimized EMS system, as evidenced by the 
rapid EMS response and time to thrombolysis. 
Furthermore, the authors selected a patient population 
with potential for a favorable outcome, as evidenced by 
the 30-day survival of 17% in the placebo group compared 
to 10% in most studies [9]. Th   e corollary to this is that the 
incremental beneﬁ  t of pre-hospital advanced life support 
beyond early CPR and deﬁ  brillation tends to be minimal, 
a lesson learned from Th   e Ontario Prehospital Advanced 
Life Support (OPALS) study [10].
Recommendation
Based on the results of the TROICA trial, there seems to 
be no beneﬁ   t from the use of tenecteplase without 
adjunctive antithrombotic therapy in out-of-hospital 
cardiac arrest. No such conclusion can be made regarding 
the subgroup of patients with suspected pulmonary 
embolism and the results should not be generalized to 
the inpatient setting.
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